Acadian Asset Management
ARQT icon

Acadian Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Acadian Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72K Sell
2,755
-3,578
-56% -$83.4K ﹤0.01% 1814
2026
Q1 		$149K Sell
6,333
-13,779
-69% -$352K ﹤0.01% 1657
2025
Q4 		$583K Buy
+20,112
New +$515K ﹤0.01% 1261
2024
Q4 		– Sell
-6,680
Closed -$62K – 1631
2024
Q3 		$62K Sell
6,680
-153,348
-96% -$1.51M ﹤0.01% 1743
2024
Q2 		$1.49M Buy
+160,028
New +$1.45M ﹤0.01% 868
2024
Q1 		– Sell
-354,112
Closed -$1.14M – 1562
2023
Q4 		$1.14M Buy
+354,112
New +$963K ﹤0.01% 823

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management's ARQT Position: Q2 2026 in Review

Acadian Asset Management reduced its Arcutis Biotherapeutics (ARQT) stake by 56% in Q2 2026, selling an estimated $83.4K and leaving 2,755 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #1814.

Acadian Asset Management first reported a position in ARQT in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.49M in Q2 2024. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Acadian Asset Management held 2,755 shares of Arcutis Biotherapeutics worth $72K as of Q2 2026.
  • Acadian Asset Management sold 3,578 Arcutis Biotherapeutics shares in Q2 2026, an estimated $83.4K.
  • Arcutis Biotherapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1814 holding.
  • Acadian Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 6 quarters since.
  • Acadian Asset Management's Arcutis Biotherapeutics position peaked at $1.49M in Q2 2024.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.